lncRNA-Xist/miR-101-3p/KLF6/C/EBPα axis promotes TAM polarization to regulate cancer cell proliferation and migration

The phenotypic switch in tumor-associated macrophages (TAMs) mediates immunity escape of cancer. However, the underlying mechanisms in the TAM phenotypic switch have not been systematically elucidated. In this study, long noncoding RNA (lncRNA)-Xist, CCAAT/enhancer-binding protein (C/EBP)α, and Krup...

Full description

Bibliographic Details
Main Authors: Yanyun Zhao, Zhaojin Yu, Rong Ma, Yifan Zhang, Lin Zhao, Yuanyuan Yan, Xuemei Lv, Liwen Zhang, Panpan Su, Jia Bi, Hong Xu, Miao He, Minjie Wei
Format: Article
Language:English
Published: Elsevier 2021-03-01
Series:Molecular Therapy: Nucleic Acids
Subjects:
Online Access:http://www.sciencedirect.com/science/article/pii/S2162253120303863
id doaj-7a8d76d7b3dd4137aa8a3d728c7a323a
record_format Article
collection DOAJ
language English
format Article
sources DOAJ
author Yanyun Zhao
Zhaojin Yu
Rong Ma
Yifan Zhang
Lin Zhao
Yuanyuan Yan
Xuemei Lv
Liwen Zhang
Panpan Su
Jia Bi
Hong Xu
Miao He
Minjie Wei
spellingShingle Yanyun Zhao
Zhaojin Yu
Rong Ma
Yifan Zhang
Lin Zhao
Yuanyuan Yan
Xuemei Lv
Liwen Zhang
Panpan Su
Jia Bi
Hong Xu
Miao He
Minjie Wei
lncRNA-Xist/miR-101-3p/KLF6/C/EBPα axis promotes TAM polarization to regulate cancer cell proliferation and migration
Molecular Therapy: Nucleic Acids
tumor-associated macrophages
polarization
lncRNA Xist
ceRNA
miR-101
author_facet Yanyun Zhao
Zhaojin Yu
Rong Ma
Yifan Zhang
Lin Zhao
Yuanyuan Yan
Xuemei Lv
Liwen Zhang
Panpan Su
Jia Bi
Hong Xu
Miao He
Minjie Wei
author_sort Yanyun Zhao
title lncRNA-Xist/miR-101-3p/KLF6/C/EBPα axis promotes TAM polarization to regulate cancer cell proliferation and migration
title_short lncRNA-Xist/miR-101-3p/KLF6/C/EBPα axis promotes TAM polarization to regulate cancer cell proliferation and migration
title_full lncRNA-Xist/miR-101-3p/KLF6/C/EBPα axis promotes TAM polarization to regulate cancer cell proliferation and migration
title_fullStr lncRNA-Xist/miR-101-3p/KLF6/C/EBPα axis promotes TAM polarization to regulate cancer cell proliferation and migration
title_full_unstemmed lncRNA-Xist/miR-101-3p/KLF6/C/EBPα axis promotes TAM polarization to regulate cancer cell proliferation and migration
title_sort lncrna-xist/mir-101-3p/klf6/c/ebpα axis promotes tam polarization to regulate cancer cell proliferation and migration
publisher Elsevier
series Molecular Therapy: Nucleic Acids
issn 2162-2531
publishDate 2021-03-01
description The phenotypic switch in tumor-associated macrophages (TAMs) mediates immunity escape of cancer. However, the underlying mechanisms in the TAM phenotypic switch have not been systematically elucidated. In this study, long noncoding RNA (lncRNA)-Xist, CCAAT/enhancer-binding protein (C/EBP)α, and Kruppel-like factor 6 (KLF6) were upregulated, whereas microRNA (miR)-101 was downregulated in M1 macrophages-type (M1). Knockdown of Xist or overexpression of miR-101 in M1 could induce M1-to-M2 macrophage-type (M2) conversion to promote cell proliferation and migration of breast and ovarian cancer by inhibiting C/EBPα and KLF6 expression. Furthermore, miR-101 could combine with both Xist and C/EBPα and KLF6 through the same microRNA response element (MRE) predicted by bioinformatics and verified by luciferase reporter assays. Moreover, we found that miR-101 knockdown restored the decreased M1 marker and the increased M2 marker expression and also reversed the promotion of proliferation and migration of human breast cancer cells (MCF-7) and human ovarian cancer (OV) cells caused by silencing Xist. Generally, the present study indicates that Xist could mediate macrophage polarization to affect cell proliferation and migration of breast and ovarian cancer by competing with miR-101 to regulate C/EBPα and KLF6 expression. The promotion of Xist expression in M1 macrophages and inhibition of miR-101 expression in M2 macrophages might play an important role in inhibiting breast and ovarian tumor proliferation and migration abilities.
topic tumor-associated macrophages
polarization
lncRNA Xist
ceRNA
miR-101
url http://www.sciencedirect.com/science/article/pii/S2162253120303863
work_keys_str_mv AT yanyunzhao lncrnaxistmir1013pklf6cebpaaxispromotestampolarizationtoregulatecancercellproliferationandmigration
AT zhaojinyu lncrnaxistmir1013pklf6cebpaaxispromotestampolarizationtoregulatecancercellproliferationandmigration
AT rongma lncrnaxistmir1013pklf6cebpaaxispromotestampolarizationtoregulatecancercellproliferationandmigration
AT yifanzhang lncrnaxistmir1013pklf6cebpaaxispromotestampolarizationtoregulatecancercellproliferationandmigration
AT linzhao lncrnaxistmir1013pklf6cebpaaxispromotestampolarizationtoregulatecancercellproliferationandmigration
AT yuanyuanyan lncrnaxistmir1013pklf6cebpaaxispromotestampolarizationtoregulatecancercellproliferationandmigration
AT xuemeilv lncrnaxistmir1013pklf6cebpaaxispromotestampolarizationtoregulatecancercellproliferationandmigration
AT liwenzhang lncrnaxistmir1013pklf6cebpaaxispromotestampolarizationtoregulatecancercellproliferationandmigration
AT panpansu lncrnaxistmir1013pklf6cebpaaxispromotestampolarizationtoregulatecancercellproliferationandmigration
AT jiabi lncrnaxistmir1013pklf6cebpaaxispromotestampolarizationtoregulatecancercellproliferationandmigration
AT hongxu lncrnaxistmir1013pklf6cebpaaxispromotestampolarizationtoregulatecancercellproliferationandmigration
AT miaohe lncrnaxistmir1013pklf6cebpaaxispromotestampolarizationtoregulatecancercellproliferationandmigration
AT minjiewei lncrnaxistmir1013pklf6cebpaaxispromotestampolarizationtoregulatecancercellproliferationandmigration
_version_ 1724229413627756544
spelling doaj-7a8d76d7b3dd4137aa8a3d728c7a323a2021-03-07T04:27:54ZengElsevierMolecular Therapy: Nucleic Acids2162-25312021-03-0123536551lncRNA-Xist/miR-101-3p/KLF6/C/EBPα axis promotes TAM polarization to regulate cancer cell proliferation and migrationYanyun Zhao0Zhaojin Yu1Rong Ma2Yifan Zhang3Lin Zhao4Yuanyuan Yan5Xuemei Lv6Liwen Zhang7Panpan Su8Jia Bi9Hong Xu10Miao He11Minjie Wei12Department of Pharmacology, School of Pharmacy, China Medical University, Shenyang City, 110122 Liaoning Province, China; Liaoning Key Laboratory of Molecular Targeted Anti-Tumor Drug Development and Evaluation, Liaoning Cancer Immune Peptide Drug Engineering Technology Research Center, Key Laboratory of Precision Diagnosis and Treatment of Gastrointestinal Tumors, Ministry of Education, China Medical University, Shenyang, Liaoning Province, ChinaDepartment of Pharmacology, School of Pharmacy, China Medical University, Shenyang City, 110122 Liaoning Province, China; Liaoning Key Laboratory of Molecular Targeted Anti-Tumor Drug Development and Evaluation, Liaoning Cancer Immune Peptide Drug Engineering Technology Research Center, Key Laboratory of Precision Diagnosis and Treatment of Gastrointestinal Tumors, Ministry of Education, China Medical University, Shenyang, Liaoning Province, ChinaDepartment of Pharmacology, School of Pharmacy, China Medical University, Shenyang City, 110122 Liaoning Province, China; Liaoning Key Laboratory of Molecular Targeted Anti-Tumor Drug Development and Evaluation, Liaoning Cancer Immune Peptide Drug Engineering Technology Research Center, Key Laboratory of Precision Diagnosis and Treatment of Gastrointestinal Tumors, Ministry of Education, China Medical University, Shenyang, Liaoning Province, ChinaDepartment of Pharmacology, School of Pharmacy, China Medical University, Shenyang City, 110122 Liaoning Province, China; Liaoning Key Laboratory of Molecular Targeted Anti-Tumor Drug Development and Evaluation, Liaoning Cancer Immune Peptide Drug Engineering Technology Research Center, Key Laboratory of Precision Diagnosis and Treatment of Gastrointestinal Tumors, Ministry of Education, China Medical University, Shenyang, Liaoning Province, ChinaDepartment of Pharmacology, School of Pharmacy, China Medical University, Shenyang City, 110122 Liaoning Province, China; Liaoning Key Laboratory of Molecular Targeted Anti-Tumor Drug Development and Evaluation, Liaoning Cancer Immune Peptide Drug Engineering Technology Research Center, Key Laboratory of Precision Diagnosis and Treatment of Gastrointestinal Tumors, Ministry of Education, China Medical University, Shenyang, Liaoning Province, ChinaDepartment of Pharmacology, School of Pharmacy, China Medical University, Shenyang City, 110122 Liaoning Province, China; Liaoning Key Laboratory of Molecular Targeted Anti-Tumor Drug Development and Evaluation, Liaoning Cancer Immune Peptide Drug Engineering Technology Research Center, Key Laboratory of Precision Diagnosis and Treatment of Gastrointestinal Tumors, Ministry of Education, China Medical University, Shenyang, Liaoning Province, ChinaDepartment of Pharmacology, School of Pharmacy, China Medical University, Shenyang City, 110122 Liaoning Province, China; Liaoning Key Laboratory of Molecular Targeted Anti-Tumor Drug Development and Evaluation, Liaoning Cancer Immune Peptide Drug Engineering Technology Research Center, Key Laboratory of Precision Diagnosis and Treatment of Gastrointestinal Tumors, Ministry of Education, China Medical University, Shenyang, Liaoning Province, ChinaDepartment of Pharmacology, School of Pharmacy, China Medical University, Shenyang City, 110122 Liaoning Province, China; Liaoning Key Laboratory of Molecular Targeted Anti-Tumor Drug Development and Evaluation, Liaoning Cancer Immune Peptide Drug Engineering Technology Research Center, Key Laboratory of Precision Diagnosis and Treatment of Gastrointestinal Tumors, Ministry of Education, China Medical University, Shenyang, Liaoning Province, ChinaDepartment of Pharmacology, School of Pharmacy, China Medical University, Shenyang City, 110122 Liaoning Province, China; Liaoning Key Laboratory of Molecular Targeted Anti-Tumor Drug Development and Evaluation, Liaoning Cancer Immune Peptide Drug Engineering Technology Research Center, Key Laboratory of Precision Diagnosis and Treatment of Gastrointestinal Tumors, Ministry of Education, China Medical University, Shenyang, Liaoning Province, ChinaDepartment of Pharmacology, School of Pharmacy, China Medical University, Shenyang City, 110122 Liaoning Province, China; Liaoning Key Laboratory of Molecular Targeted Anti-Tumor Drug Development and Evaluation, Liaoning Cancer Immune Peptide Drug Engineering Technology Research Center, Key Laboratory of Precision Diagnosis and Treatment of Gastrointestinal Tumors, Ministry of Education, China Medical University, Shenyang, Liaoning Province, ChinaDepartment of Breast Cancer, Cancer Hospital of China Medical University, Dadong District, 110042 Shenyang, China; Corresponding author: Hong Xu, Department of Breast Cancer, Cancer Hospital of China Medical University, No. 44 Xiaoheyan Road, Dadong District, 110042 Shenyang, China.Department of Pharmacology, School of Pharmacy, China Medical University, Shenyang City, 110122 Liaoning Province, China; Liaoning Key Laboratory of Molecular Targeted Anti-Tumor Drug Development and Evaluation, Liaoning Cancer Immune Peptide Drug Engineering Technology Research Center, Key Laboratory of Precision Diagnosis and Treatment of Gastrointestinal Tumors, Ministry of Education, China Medical University, Shenyang, Liaoning Province, China; Corresponding author: Miao He, Department of Pharmacology, School of Pharmacy, China Medical University, No. 77 Puhe Road, Shenyang North New Area, Shenyang City, 110122 Liaoning Province, China.Department of Pharmacology, School of Pharmacy, China Medical University, Shenyang City, 110122 Liaoning Province, China; Liaoning Key Laboratory of Molecular Targeted Anti-Tumor Drug Development and Evaluation, Liaoning Cancer Immune Peptide Drug Engineering Technology Research Center, Key Laboratory of Precision Diagnosis and Treatment of Gastrointestinal Tumors, Ministry of Education, China Medical University, Shenyang, Liaoning Province, China; Corresponding author: Minjie Wei, Department of Pharmacology, School of Pharmacy, China Medical University, No. 77 Puhe Road, Shenyang North New Area, Shenyang City, 110122 Liaoning Province, China.The phenotypic switch in tumor-associated macrophages (TAMs) mediates immunity escape of cancer. However, the underlying mechanisms in the TAM phenotypic switch have not been systematically elucidated. In this study, long noncoding RNA (lncRNA)-Xist, CCAAT/enhancer-binding protein (C/EBP)α, and Kruppel-like factor 6 (KLF6) were upregulated, whereas microRNA (miR)-101 was downregulated in M1 macrophages-type (M1). Knockdown of Xist or overexpression of miR-101 in M1 could induce M1-to-M2 macrophage-type (M2) conversion to promote cell proliferation and migration of breast and ovarian cancer by inhibiting C/EBPα and KLF6 expression. Furthermore, miR-101 could combine with both Xist and C/EBPα and KLF6 through the same microRNA response element (MRE) predicted by bioinformatics and verified by luciferase reporter assays. Moreover, we found that miR-101 knockdown restored the decreased M1 marker and the increased M2 marker expression and also reversed the promotion of proliferation and migration of human breast cancer cells (MCF-7) and human ovarian cancer (OV) cells caused by silencing Xist. Generally, the present study indicates that Xist could mediate macrophage polarization to affect cell proliferation and migration of breast and ovarian cancer by competing with miR-101 to regulate C/EBPα and KLF6 expression. The promotion of Xist expression in M1 macrophages and inhibition of miR-101 expression in M2 macrophages might play an important role in inhibiting breast and ovarian tumor proliferation and migration abilities.http://www.sciencedirect.com/science/article/pii/S2162253120303863tumor-associated macrophagespolarizationlncRNA XistceRNAmiR-101